Advertisement

Topics

Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy

03:40 EDT 5 Aug 2017 | SCRIP

Lilly will submit lasmiditan for FDA approval after a second positive Phase III study, giving the company a product to...

      

Related Stories

 

Original Article: Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy

NEXT ARTICLE

More From BioPortfolio on "Phase III Lasmiditan Data Strengthens Lilly's Dual Migraine Strategy"

Quick Search
Advertisement
 

Relevant Topics

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...